Peptide News Digest

#Mfn-Pricing

3 stories

Industry · View digest

Novo Nordisk (NYSE: NVO) Shares Fell Approximately 5% Tuesday-Wednesday Following the August 4 H1 2026 Earnings Release as CEO Lars Fruergaard Jorgensen Defended Wegovy Pill Economics on the Earnings Call While Analysts Focus on the Compressed Margin Trajectory From the Most-Favored-Nation Pricing Deals With the Trump Administration (November 2025) and the Medicare GLP-1 Bridge Program (Launched July 1) That Both Reduce Net Realized Prices Per Unit Even as Prescription Volume Climbs; Wegovy Pill Has Reached More Than 5 Million Cumulative US Prescriptions Since Q1 2026 Launch

Novo Nordisk (NYSE: NVO) shares fell approximately 5% across Tuesday and Wednesday August 4-5, 2026 following the H1 2026 earnings release. CEO Lars Fruergaard Jorgensen defended Wegovy pill economics on the earnings call, addressing analyst concerns about the compressed margin trajectory from the Most-Favored-Nation pricing deals announced with the Trump administration in November 2025 (which paired lower drug prices with expanded Medicare access and a three-year tariff grace period) and the Medicare GLP-1 Bridge Program launched July 1, 2026 (providing Wegovy, Zepbound KwikPen, and Foundayo at a capped $50/month copay for eligible Medicare Part D beneficiaries through December 31, 2027). Both programs reduce net realized prices per unit even as prescription volume climbs. Wegovy pill (oral semaglutide 25/50 mg for obesity) has reached more than 5 million cumulative US prescriptions since the Q1 2026 launch, one of the fastest oral obesity-drug uptake curves on record. Novo Nordisk H1 2026 sales reached 78.49 billion Danish kroner ($12.09 billion, +3% constant currency); the company raised full-year 2026 guidance from prior expectations to down 6% to flat at constant exchange rates. Analyst attention now focuses on 2027 pricing environment and Novo's ability to defend franchise economics as Eli Lilly's tirzepatide and orforglipron continue to widen the competitive gap.

Industry · View digest

Medicare GLP-1 Bridge Program Marks 27 Days Since the July 1, 2026 CMS Pilot Launch That Provides All Formulations of Wegovy (Semaglutide, Novo Nordisk), the KwikPen Formulation of Zepbound (Tirzepatide, Eli Lilly), and All Formulations of Foundayo (Orforglipron, Eli Lilly) at a Capped $50 Monthly Copay for Eligible Medicare Part D Beneficiaries Through December 31, 2027; KFF Analysis Estimates Approximately 3.8 Million Medicare Beneficiaries Meet the Clinical Eligibility Criteria for the Program (~8% of the 47.5 Million Part D Enrollees Nationally), Though CMS Has Not Yet Released Actual Enrollment Data From the First Program Month

The Centers for Medicare & Medicaid Services (CMS) Medicare GLP-1 Bridge Program is 27 days into the July 1, 2026 pilot launch. The program provides eligible Medicare Part D beneficiaries access to specified GLP-1 receptor agonist products at a capped $50 monthly out-of-pocket cost through December 31, 2027. Covered products include all formulations of Wegovy (semaglutide, Novo Nordisk), the KwikPen formulation of Zepbound (tirzepatide, Eli Lilly), and all formulations of Foundayo (orforglipron, Eli Lilly). The program was created through a Most-Favored-Nation (MFN) pricing agreement announced by the Trump administration in Q1 2026 that pairs manufacturer discounts with a fixed patient copay. A KFF (Kaiser Family Foundation) analysis estimates approximately 3.8 million Medicare beneficiaries meet the program's clinical eligibility criteria (obesity with BMI ≥ 30 kg/m² and specific cardiovascular or metabolic comorbidities), representing approximately 8% of the 47.5 million Part D enrollees nationally. CMS has not yet released actual enrollment data from the first program month. The program's actual utilization pattern, adherence rate, and expenditure trajectory will inform whether the pilot is extended past December 31, 2027 or converted to a permanent Medicare Part D obesity benefit.

Regulatory · View digest

USTR Launches Section 301 Investigation into Germany's Persistent Underpayment for Innovative Pharmaceutical Products (June 18, 2026) — 9% Confidential-Pricing Discount + Draft 2027 Mandatory Patented-Medicine Rebate in Scope

The Office of the U.S. Trade Representative initiated a Section 301 investigation into Germany's pricing practices for innovative pharmaceuticals on June 18, 2026, alleging that Germany's persistent underpayment for innovative pharmaceutical products is unreasonable or discriminatory and burdens or restricts U.S. commerce. The investigation focuses on Germany's 9% price discount tied to pricing confidentiality and on draft 2026 German legislation that would add a mandatory rebate on patented medicines starting in 2027. The USTR public comment docket opens June 25, with submissions due by August 10 and a hearing scheduled for September 22, 2026. The investigation extends the most-favored-nation drug-pricing pressure President Trump applied to Lilly and Novo Nordisk under the TrumpRx framework toward European pricing regimes; if USTR finds Germany's practices harm US commerce, retaliatory tariffs on German pharmaceutical exports are among the available remedies — a meaningful threat to GLP-1 supply chains given Bachem and Boehringer Ingelheim's German manufacturing footprint.